A novel Chinese randomized trial demonstrated weekly nausea prophylaxis with the NK1 antagonist aprepitant significantly reduced emesis and nausea among patients receiving chemoradiation for nasopharyngeal cancer, particularly those with a mean brainstem dose of ≥36 Gy. | Yang, JAMA Netw Open 2023
